Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
AH Equity Partners Bio II, L.L.C. (CIK 1725722) reported $143.5M across 4 reported positions in its SEC 13F filing for 2022-09-30. Largest positions: EQRX ($86.3M, 60.15%), NAUT ($34.6M, 24.08%), ERAS ($19.5M, 13.59%), NVTA ($3.1M, 2.19%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | EQRX | EQRx, Inc. | $86.3M | 60.15% | 17.4M | Hold |
| 2 | NAUT | Nautilus Biotechnology, Inc. | $34.6M | 24.08% | 16.3M | Hold |
| 3 | ERAS | Erasca, Inc. | $19.5M | 13.59% | 2.5M | Hold |
| 4 | NVTA | InVitae Corporation | $3.1M | 2.19% | 1.3M | Added |
Source: SEC Form 13F filings · as of 2022-09-30